CONMED Corporation — Q3 2022 Form 10-Q Summary
Business Context and Reporting Period
CONMED is a medical technology company providing surgical devices and equipment for minimally invasive procedures, primarily in orthopedic and general surgery. This unaudited filing covers the three and nine months ended September 30, 2022, compared with the corresponding 2021 periods.
- Approximately 83% of revenue is derived from single-use products.
- International sales represented approximately 45% of consolidated sales for both nine-month periods.
- CONMED acquired In2Bones on June 13, 2022 and Biorez on August 9, 2022.
Key Financial Metrics
| Metric | Q3 2022 | Q3 2021 | 9M 2022 | 9M 2021 |
|---|---|---|---|---|
| Net sales | $275.1 million | $248.8 million | $794.6 million | $736.7 million |
| Gross profit | $151.6 million | $142.3 million | $439.4 million | $412.2 million |
| Gross margin | 55.1% | 57.2% | 55.3% | 56.0% |
| Income from operations | $24.2 million | $26.7 million | $71.1 million | $72.5 million |
| Operating margin | 8.8% | 10.7% | 9.0% | 9.8% |
| Net income (loss) | $46.2 million | $14.9 million | $(107.2) million | $38.1 million |
| Diluted EPS | $1.48 | $0.47 | $(3.59) | $1.19 |
| Net cash from operating activities | Not separately reported | Not separately reported | $45.0 million | $78.0 million |
- Q3 revenue increased 10.6% as reported and 12.1% on a constant-currency basis. Nine-month revenue increased 7.9% as reported and 8.8% on a constant-currency basis.
- Q3 orthopedic surgery revenue increased 12.2% and general surgery revenue increased 9.4%. Nine-month increases were 8.0% and 7.8%, respectively.
- Single-use product sales increased 15.1% in Q3 and 11.0% for the nine-month period. Capital product sales declined 8.5% and 5.6%, respectively.
- Cash and cash equivalents were $33.4 million at September 30, 2022, compared with $20.8 million at December 31, 2021.
- Inventories increased to $304.8 million from $231.6 million, primarily reflecting efforts to mitigate supply-chain challenges.
- Total debt was $1.04 billion at September 30, 2022, compared with $684.7 million at December 31, 2021. Available revolving-credit capacity was $530.2 million, with approximately $1.8 million reserved for letters of credit.
Material Changes Versus the Prior Comparable Period
- Revenue growth was partly offset by a 210-basis-point Q3 gross-margin decline and a 70-basis-point nine-month decline. Management attributed the pressure primarily to inflation, higher raw-material and freight costs, production variances, and $2.1 million of Q3 inventory step-up costs related to In2Bones.
- Operating income declined 9.2% in Q3 and 1.9% for the nine-month period despite higher sales, reflecting margin pressure and acquisition-related costs.
- Q3 net income benefited from a $30.4 million income-tax benefit. The nine-month net loss principally reflected $112.0 million of other expense, including a $103.1 million conversion premium, $5.5 million of convertible-note hedge settlement costs, and $3.4 million of debt-related write-offs.
- Operating cash flow declined $33.0 million year over year to $45.0 million, driven by higher accounts receivable and inventory investment, higher incentive compensation payments, and supply-chain-related working-capital needs.
- Investing cash outflows increased to $243.2 million, including $227.1 million for acquisitions and $16.1 million of capital expenditures.
- CONMED issued $800.0 million of 2.250% convertible notes due 2027, repurchased and extinguished $275.0 million of 2.625% convertible notes, prepaid $90.0 million of term debt, and reduced its revolving-credit borrowings.
Guidance, Outlook, Risks, Contingencies and Unusual Items
- The filing does not provide a clear quantitative full-year revenue or earnings guidance figure.
- Management expects inflationary pressures, supply-chain constraints, staffing shortages, and COVID-19-related variability to continue affecting operations during 2022. The company stated that it may need additional cost reductions or debt refinancing.
- The In2Bones acquisition included potential earn-out payments of up to $110.0 million. Biorez included potential earn-outs of up to $165.0 million. These liabilities are based on Level 3 valuation inputs and could change materially with projected revenue, payment timing, probabilities, or discount rates.
- In2Bones contributed $10.0 million of Q3 sales and $12.1 million since acquisition. Biorez sales and earnings were immaterial through September 30, 2022.
- CONMED reported pending litigation involving alleged ethylene oxide exposure and related insurance-coverage disputes. The company has not recorded a liability for potential damages because losses were not considered probable or estimable; the possible loss range was not clear in the filing.
- Product liability, regulatory and FCPA compliance, cybersecurity, intellectual-property, environmental, foreign-exchange, interest-rate, acquisition-integration, and allograft-supply risks remain material considerations.
- The company reported compliance with its credit agreement covenants and effective disclosure controls as of September 30, 2022.
Most Important Facts for Investors to Verify
- Whether revenue growth and acquired-product contribution offset continuing gross-margin pressure from inflation and supply-chain costs.
- The sustainability of operating cash flow after the significant inventory and acquisition-related investments.
- Debt-service capacity, refinancing requirements, covenant compliance, and the effect of variable-rate borrowings.
- The ultimate amount and timing of In2Bones and Biorez earn-out payments.
- The recurring versus nonrecurring nature of the $112.0 million of nine-month other expense and the resulting tax effects.
- Progress integrating the acquisitions and the commercial development of Biorez products.
- Potential exposure from ethylene oxide litigation, insurance-coverage appeals, product liability, and other regulatory or environmental matters.